Biogen Inc. announced the completion of its acquisition of RayThera Inc., a privately held biotechnology company specializing in small-molecule immunology therapies. The acquisition adds multiple assets to Biogen's immunology portfolio, with the lead program entering Phase 1 development in July 2026. The company views this as part of its strategic growth in immunology and its open innovation model.

Supernus Pharmaceuticals announced a merger with Indivior Pharmaceuticals in an all-stock deal, creating a combined company with 11 FDA-approved drugs and anticipated $125 million in annual cost synergies. The stock rose 3% despite initial gains of 16%, reflecting cautious optimism. Q2 earnings showed 32% revenue growth to $219 million but a net loss of $58 million, missing earnings estimates while beating revenue forecasts.

The Vanguard Health Care ETF (VHT) offers broad healthcare exposure with a low 0.09% expense ratio and 423 holdings, while the Invesco Biotechnology & Genome ETF (PBE) provides focused biotech exposure with 31 holdings and higher growth potential. PBE delivered a stronger 40.88% one-year return but experienced greater volatility with a 37.84% maximum drawdown, while VHT returned 27.85% with lower risk. VHT suits conservative investors seeking steady, low-cost exposure, while PBE appeals to risk-tolerant investors chasing biotech innovation.

Biogen stock gained nearly 2% after beating analyst estimates on both revenue ($2.7B, up 3% YoY) and adjusted EPS ($3.60 vs. $3.17 expected). The company's growth portfolio drove top-line improvement with 24% YoY revenue growth. Despite cutting full-year adjusted net income guidance to $12-$13 per share from $14.25-$15.25, investors remained positive as the company raised revenue guidance to mid-single-digit growth for 2025, signaling successful business pivot.

The global autoimmune disease therapeutics market is projected to grow from USD 80.54 billion in 2025 to USD 137.85 billion by 2035, with a CAGR of 5.52%. Growth is driven by rising prevalence of autoimmune diseases, adoption of biologics, JAK inhibitors, monoclonal antibodies, and precision medicine technologies. North America leads with 39.96% market share, while Asia-Pacific shows the fastest growth at 6.28% CAGR.

Grey Matters Health Inc. has received its first brain-dedicated PET scanning system (CareMiBrain) for its flagship NovaScan Neuroimaging Clinic in Davie, Florida, positioning itself as the first U.S. clinic to offer brain-only PET scans for early Alzheimer's detection. The clinic will capitalize on the emerging billion-dollar market created by FDA-approved monoclonal antibody treatments (Leqembi and Kisunla) that require beta-amyloid brain imaging for patient authorization and monitoring.

Biogen announced a $1 billion acquisition of RayThera, a company with anti-inflammatory assets targeting immune-mediated conditions. This strategic move strengthens Biogen's immunology portfolio following its earlier acquisition of Apellis Pharmaceuticals. The company is successfully transitioning from its declining MS drug business to growth areas like Alzheimer's and rare diseases, with early signs of business stabilization and revenue growth.

A federal court has approved an $18.9 million settlement for investors who purchased Biogen Inc. common stock between June 8, 2021 and July 12, 2021. A settlement hearing is scheduled for September 29, 2026, to determine if the settlement is fair and reasonable. Class members must submit a Proof of Claim by September 24, 2026 to receive compensation.

Pomerantz LLP is investigating Biogen Inc. for potential securities fraud following the company's announcement of Phase 2 CELIA study results for diranersen (BIIB080), an Alzheimer's disease treatment. Although Biogen described the results as 'compelling,' the study missed its primary dose-response endpoint, causing the stock to fall $13.16 per share (6.43%) to $191.37 on May 14, 2026.

The cutaneous lupus erythematosus (CLE) market is projected to grow at 8% CAGR through 2036, driven by emerging targeted therapies and increased disease awareness. The market was valued at USD 650 million in 2025 across seven major markets. Key pipeline drugs from major pharmaceutical companies targeting plasmacytoid dendritic cells and type I interferon pathways are expected to transform treatment options for CLE patients.

Biogen agreed to acquire private biotechnology company RayThera for up to $1 billion to expand its immunology pipeline. The deal includes an upfront payment with the majority tied to future clinical and regulatory milestones, expected to close in Q3 2026. RayThera focuses on small-molecule therapies for immunological diseases with a lead candidate entering Phase 1 development in early Q3 2026.

Denali Therapeutics announced it will sell its Rare Pediatric Disease Priority Review Voucher for $195 million following FDA approval of AVLAYAH, the first FDA-approved biologic designed to cross the blood-brain barrier. The proceeds will support advancement of Denali's clinical pipeline for lysosomal storage disorders and neurodegenerative diseases. However, the article also notes that Biogen and Denali's Phase 2b LUMA study of BIIB122 in early-stage Parkinson's disease failed to meet its primary and secondary endpoints, leading to discontinuation of the program.